The Pandemic Ripple Effect: Understanding Marketing and Public Policy Opportunities in the Pharmaceutical Industry

Abstract

Get full access to this article

View all access options for this article.

References

Bloomberg News (2020), “Global Rush for Trump-Backed Virus Drug Sparks India Export Ban,” (March 25), https://www.bloomberg.com/news/articles/2020-03-25/india-bans-exports-of-trump-backed-virus-drug-as-demand-surges.

Bradford

David W.

Turner

John L.

Williams

Jonathan W.

(2018), “Off-Label Use of Pharmaceuticals: A Detection Controlled Estimation Approach,” Journal of Industrial Economies, 66 (4), 866–903.

Cohen

Jon

(2020), “The $1 Billion Bet: Pharma Giant and U.S. Government Team Up in All-Out Coronavirus Vaccine Push,” Science (March 31), https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-government-team-all-out-coronavirus-vaccine-push#.

Fink

Jenni

(2020), “South Dakota Will Become First to Hold Statewide Clinical Trial of Hydroxychloroquine to Treat Coronavirus,” Newsweek (April 13), https://www.newsweek.com/south-dakota-start-hydroxychloroquine-clinical-trials-coronavirus-1497585.

Miller

Elizabeth Gelfand

Luce

Mary Frances

Kahn

Barbara E.

Conant

Emily F.

(2009), “Understanding Emotional Reactions for Negative Services: The Impact of Efficacy Beliefs and Stage in Process,” Journal of Service Research, 12 (1), 87–99.

U.S. Food and Drug Administration (2018), “Understanding Unapproved Use of Approved Drugs ‘Off-Label’,” (accessed April 14, 2020), https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label.

U.S. Food and Drug Administration (2020a), “Fact Sheet for Patients and Parent/Caregivers Emergency Use Authorization (EUA) of Hydroxychloroquine Sulfate for Treatment of Covid-19 in Certain Hospitalized Patients,” (accessed April 17, 2020), https://www.fda.gov/media/136538/download.

U.S. Food and Drug Administration (2020b), “Fact Sheet for Patients and Parent/Caregivers Emergency Use Authorization (EUA) of Remdesivir for Coronavirus Disease 2019 (COVID-19),” (accessed May 3, 2020), https://www.fda.gov/media/137565/download.

U.S. Food and Drug Administration (2020c), “Remdesivir EUA Letter of Authorization,” (accessed May 3, 2020), https://www.fda.gov/media/137564/download.